EUVIMEDEUVIMED entdecken
Vergleichsstudie

Head-to-Head Comparison of Caco-2 Transwell and Gut-on-a-Chip Models for Assessing Oral Peptide Formulations

John P Gleeson iD, Stephanie Y Zhang iD, Natalia Subelzu, Jing Ling, Becky Nissley, Whitney Ong, Rebecca Nofsinger, Filippos Kesisoglou

Molecular Pharmaceutics · 05.08.2024 · 21 (8) · 3880-3888

DOI: 10.1021/acs.molpharmaceut.4c00210 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Molecular Pharmaceutics, online erschienen am 28.06.2024. Verfasst von John P Gleeson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, New Jersey 07065, United States. Hauptthemen laut MEDLINE: Peptides, Intestinal Absorption, Permeability. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral delivery of potent peptide drugs provides key formulation challenges in the pharmaceutical industry: stability, solubility, and permeability. Intestinal permeation enhancers (PEs) can overcome the low oral bioavailability by improving the drug permeability. Conventional in vitro and ex vivo models for assessing PEs fail to predict efficacy in vivo. Here, we compared Caco-2 cells cultured in the conventional static Transwell model to a commercially available continuous flow microfluidic Gut-on-a-Chip model. We determined baseline permeability of FITC-Dextan 3 kDa (FD3) in Transwell (5.3 ± 0.8 × 10-8 cm/s) vs Chip (3.2 ± 1.8 × 10-7 cm/s). We screened the concentration impact of two established PEs sodium caprate and sucrose monolaurate and indicated a requirement for higher enhancer concentration in the Chip model to elicit equivalent efficacy e.g., 10 mM sodium caprate in Transwells vs 25 mM in Chips. Fasted and fed state simulated intestinal fluids (FaSSIF/FeSSIF) were introduced into the Chip and increased basal FD3 permeability by 3-fold and 20-fold, respectively, compared to 4-fold and 4000-fold in Transwells. We assessed the utility of this model to peptides (Insulin and Octreotide) with PEs and observed much more modest permeability enhancement in the Chip model in line with observations in ex vivo and in vivo preclinical models. These data indicate that microfluidic Chip models are well suited to bridge the gap between conventional in vitro and in vivo models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidesIntestinal AbsorptionPermeabilityCaco-2 CellsHumansAdministration, OralLab-On-A-Chip DevicesDecanoic AcidsBiological AvailabilitySucroseIntestinal MucosaSolubilityDrug Compounding

Stichwörter der Autor:innen

Gut-on-a-ChipIVIVCintestinal permeation enhancersmicrofluidicsoral peptide

Substanzen

PeptidesDecanoic Acidsdecanoic acidSucrose

Autor:innen und Institutionen

  • Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Current: Eli Lilly and Company, Drug Disposition, Indianapolis, Indiana 46284, United States.

ORCID-Profile: John P Gleeson, Stephanie Y Zhang

Förderung

  • Merck

Zitieren

APA

Gleeson, J. P., Zhang, S. Y., Subelzu, N., Ling, J., Nissley, B., Ong, W., Nofsinger, R., & Kesisoglou, F. (2024). Head-to-Head Comparison of Caco-2 Transwell and Gut-on-a-Chip Models for Assessing Oral Peptide Formulations. Molecular Pharmaceutics, 21(8), 3880-3888. https://doi.org/10.1021/acs.molpharmaceut.4c00210

Vancouver

Gleeson JP, Zhang SY, Subelzu N, Ling J, Nissley B, Ong W, et al. Head-to-Head Comparison of Caco-2 Transwell and Gut-on-a-Chip Models for Assessing Oral Peptide Formulations. Molecular Pharmaceutics. 2024;21(8):3880-3888. doi:10.1021/acs.molpharmaceut.4c00210

BibTeX
@article{Gleeson2024,
  author = {Gleeson, John P and Zhang, Stephanie Y and Subelzu, Natalia and Ling, Jing and Nissley, Becky and Ong, Whitney and Nofsinger, Rebecca and Kesisoglou, Filippos},
  title = {Head-to-Head Comparison of Caco-2 Transwell and Gut-on-a-Chip Models for Assessing Oral Peptide Formulations},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {8},
  pages = {3880--3888},
  doi = {10.1021/acs.molpharmaceut.4c00210}
}
Kostenlos starten →